- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting TAM to Tame Pancreatic Cancer
Authors
Keywords
-
Journal
Targeted Oncology
Volume 15, Issue 5, Pages 579-588
Publisher
Springer Science and Business Media LLC
Online
2020-09-30
DOI
10.1007/s11523-020-00751-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells
- (2020) Maria L. Lotsberg et al. Journal of Thoracic Oncology
- Blockade of Stromal Gas6 Alters Cancer Cell Plasticity, Activates NK Cells, and Inhibits Pancreatic Cancer Metastasis
- (2020) Lucy Ireland et al. Frontiers in Immunology
- Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis
- (2020) Mitchell S von Itzstein et al. CLINICAL CHEMISTRY
- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
- (2019) Jorge Blando et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular subtypes of pancreatic cancer
- (2019) Eric A. Collisson et al. Nature Reviews Gastroenterology & Hepatology
- Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment
- (2019) Kayla V. Myers et al. Molecular Cancer
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
- (2019) Marlies J.W. Peeters et al. Cancer Immunology Research
- Checkpoint inhibitors in pancreatic cancer
- (2019) Andreas Henriksen et al. CANCER TREATMENT REVIEWS
- 460PA phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours
- (2019) J Sarantopoulos et al. ANNALS OF ONCOLOGY
- Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancer
- (2019) Masaki Morimoto et al. CANCER LETTERS
- Cancer immunotherapy: broadening the scope of targetable tumours
- (2018) Jitske van den Bulk et al. Open Biology
- Macrophage-Derived Protein S Facilitates Apoptotic Polymorphonuclear Cell Clearance by Resolution Phase Macrophages and Supports Their Reprogramming
- (2018) Delphine Lumbroso et al. Frontiers in Immunology
- Does Axl have potential as a therapeutic target in pancreatic cancer?
- (2018) Wenting Du et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation
- (2018) Junsong Zhou et al. Cell Communication and Signaling
- TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy
- (2017) Yemsratch T. Akalu et al. IMMUNOLOGICAL REVIEWS
- TAM receptor signaling in development
- (2017) Tal Burstyn-Cohen INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret A. Tempero et al. Journal of the National Comprehensive Cancer Network
- The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer
- (2017) Pingting Zhou et al. Molecular Cancer
- Apoptotic Bodies Elicit Gas6-Mediated Migration of AXL-Expressing Tumor Cells
- (2017) Annelien J.M. Zweemer et al. MOLECULAR CANCER RESEARCH
- Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression
- (2017) Canan Kasikara et al. MOLECULAR CANCER RESEARCH
- Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer
- (2017) Marguerite L. Palisoul et al. MOLECULAR CANCER THERAPEUTICS
- Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling
- (2017) Sarah K. Nelson-Taylor et al. MOLECULAR CANCER THERAPEUTICS
- GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance
- (2017) Christine Baumann et al. Molecular Oncology
- Cancer drug addiction is relayed by an ERK2-dependent phenotype switch
- (2017) Xiangjun Kong et al. NATURE
- Pancreatic cancer stroma: controversies and current insights
- (2017) Daniel Ansari et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
- (2017) Marie Schoumacher et al. Current Oncology Reports
- Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL
- (2017) Ghada Abboud-Jarrous et al. Oncotarget
- YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
- (2017) Elena Ghiso et al. NEOPLASIA
- Yes-Associated Protein 1 Promotes Adenocarcinoma Growth and Metastasis through Activation of the Receptor Tyrosine Kinase Axl
- (2017) Z-L. Cui et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer
- (2016) Shi Hu et al. CANCER LETTERS
- Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
- (2016) Lucy Ireland et al. CANCER RESEARCH
- Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase
- (2016) Stanley G. Kimani et al. Cell Communication and Signaling
- A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2016) Thomas C.C. Yau et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
- (2016) M. Scaltriti et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer
- (2016) Miles A. Miller et al. CLINICAL CANCER RESEARCH
- Sunitinib activates Axl signaling in renal cell cancer
- (2016) Johannes C. van der Mijn et al. INTERNATIONAL JOURNAL OF CANCER
- A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer
- (2016) David B. Zhen et al. INVESTIGATIONAL NEW DRUGS
- Pancreatic cancer
- (2016) Terumi Kamisawa et al. LANCET
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers
- (2016) Kavitha Balaji et al. MOLECULAR CANCER RESEARCH
- Targeting TYRO3 inhibits epithelial–mesenchymal transition and increases drug sensitivity in colon cancer
- (2016) C-W Chien et al. ONCOGENE
- Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells
- (2016) Yaqiong Tian et al. ONCOLOGY RESEARCH
- Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer
- (2016) Hawa Nalwoga et al. PLoS One
- Epidemiology of pancreatic cancer
- (2016) Milena Ilic et al. WORLD JOURNAL OF GASTROENTEROLOGY
- TAM receptors Tyro3 and Mer as novel targets in colorectal cancer
- (2016) Robin Schmitz et al. Oncotarget
- A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer
- (2016) Chih-Ming Su et al. Oncotarget
- MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma
- (2016) Ling Chen et al. Oncotarget
- Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling
- (2016) Cun Wang et al. Theranostics
- Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow
- (2016) Kenji Yumoto et al. Scientific Reports
- Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
- (2015) P. Pettazzoni et al. CANCER RESEARCH
- Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis
- (2015) Amanda Kirane et al. CANCER RESEARCH
- Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression
- (2015) Dong Gwang Lee et al. JOURNAL OF HEPATOLOGY
- Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents
- (2015) W-B Tsai et al. ONCOGENE
- Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling
- (2015) Hsiu-Mei Chen et al. Oncotarget
- Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization
- (2015) Yaiza del Pozo Martin et al. Cell Reports
- Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells
- (2015) CHUHEE LEE Molecular Medicine Reports
- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- AXL Mediates Resistance to Cetuximab Therapy
- (2014) T. M. Brand et al. CANCER RESEARCH
- Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma
- (2014) Yanyan Li et al. IUBMB LIFE
- Overexpression of MERTK Receptor Tyrosine Kinase in Epithelial Cancer Cells Drives Efferocytosis in a Gain-of-Function Capacity
- (2014) Khanh-Quynh N. Nguyen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Receptor Tyrosine Kinases, TYRO3, AXL, and MER, Demonstrate Distinct Patterns and Complex Regulation of Ligand-induced Activation
- (2014) Wen-I Tsou et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Heterogeneity of Pancreatic Cancer Metastases in a Single Patient Revealed by Quantitative Proteomics
- (2014) Min-Sik Kim et al. MOLECULAR & CELLULAR PROTEOMICS
- The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
- (2014) Magdalena Paolino et al. NATURE
- Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
- (2014) Erinn B. Rankin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy
- (2014) Robert Torka et al. NEOPLASIA
- Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma
- (2013) Hsin-Jung Lee et al. CARCINOGENESIS
- MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis
- (2013) Rebecca S. Cook et al. JOURNAL OF CLINICAL INVESTIGATION
- Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
- (2013) J. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival
- (2013) S Ammoun et al. ONCOGENE
- Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy
- (2013) W Leconet et al. ONCOGENE
- TAZ Expression as a Prognostic Indicator in Colorectal Cancer
- (2013) Hiu-Fung Yuen et al. PLoS One
- GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation
- (2013) Russell S. Taichman et al. PLoS One
- Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer
- (2013) L. Bosurgi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Biology of the TAM Receptors
- (2013) G. Lemke Cold Spring Harbor Perspectives in Biology
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer
- (2012) Anjali Mishra et al. MOLECULAR CANCER RESEARCH
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
- (2012) Martina Ott et al. PLoS One
- Axl-dependent signalling: a clinical update
- (2011) Vyacheslav A. Korshunov CLINICAL SCIENCE
- Genome-wide Characterization ofmiR-34aInduced Changes in Protein and mRNA Expression by a Combined Pulsed SILAC and Microarray Analysis
- (2011) Markus Kaller et al. MOLECULAR & CELLULAR PROTEOMICS
- Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology
- (2011) A E J Rogers et al. ONCOGENE
- Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
- (2011) G Mudduluru et al. ONCOGENE
- Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma
- (2010) Xianzhou Song et al. CANCER
- The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target
- (2010) Jan-Bart M. Koorstra et al. CANCER BIOLOGY & THERAPY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Myeloid Zinc Finger 1 Induces Migration, Invasion, and In vivo Metastasis through Axl Gene Expression in Solid Cancer
- (2010) G. Mudduluru et al. MOLECULAR CANCER RESEARCH
- Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer
- (2010) K Vuoriluoto et al. ONCOGENE
- Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia
- (2008) Chih-Chen Hong et al. CANCER LETTERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now